Google Play icon

Update: Antibody fragments expand what PET imaging can ‘see’ in mice

Share
Posted June 5, 2015

To visualize cancer throughout the body, physicians often turn to positron emission tomography (PET), which lights up areas that are metabolically active or growing, like tumors. This week in ACS Central Science, researchers report development of new PET probes composed of labeled antibody fragments that were tested in mice. These probes could someday be used to create targeted probes, giving doctors more information about tumors and how to treat them.

Combined apparatus for positron emission tomography (PET) and X-ray computer tomography (CT), Siemens Biograph. Image credit: Brudersohn via Wikimedia, CC-BY-SA-3.0

Combined apparatus for positron emission tomography (PET) and X-ray computer tomography (CT), Siemens Biograph. Image credit: Brudersohn via Wikimedia, CC-BY-SA-3.0

The most common PET imaging probe is a labeled sugar molecule called 18F-2-deoxyfluoroglucose (FDG). PET indicates those locations where a labeled FDG molecule ends up. Because tumor cells grow faster than healthy ones, they need more sugar to meet their energy requirements, and they consume much more of the labeled sugar probe.

This makes PET ideal for seeing tumors. But this method is limited because the reporter part of the molecule, 18F, is difficult to attach to other molecules and isn’t very stable. FDG molecules are also general probes, since they can be taken up wherever the body needs energy, leading to background signals. Hidde Ploegh and coworkers set out to overcome these challenges by making probes that meet all of these needs.

An 18F-labeled antibody fragment tracks pancreatic cancer in a mouse. Credit: American Chemical Soceity

An 18F-labeled antibody fragment tracks pancreatic cancer in a mouse. Credit: American Chemical Soceity

The researchers developed a method to outfit antibody fragments with FDG. To demonstrate the usefulness of this approach, they linked a labeled FDG molecule to an antibody fragment to detect pancreatic cancer. The resulting immuno-PET probe was able to visualize pancreatic cancer tumors too small to be detected in mice using the labeled FDG molecule alone.

Ploegh and coworkers conjecture that the new probes could be used in concert with the conventional ones to test both the biochemical and metabolic signatures of cancer in patients. This information could help doctors decide between different treatment options, or even to visualize the delivery of drugs.

Original scientific publication can be found at this link: “Use of 18F‐2-Fluorodeoxyglucose To Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer“, journal ACS Central Science

Source: ACS

Featured news from related categories:

Technology Org App
Google Play icon
83,279 science & technology articles

Most Popular Articles

  1. Bright Fireball Explodes Over Ontario, Meteorite Fragments Might Have Reached the Ground (August 5, 2019)
  2. Why older people smell the way they do? Japanese have even a special word for it (August 4, 2019)
  3. Terraforming the Surface of Mars with Silica Aerogel? (July 23, 2019)
  4. Swarm Autonomy Tested in Second Major DARPA OFFSET Field Experiment (August 8, 2019)
  5. Dark Matter may Predate even the Big Bang Itself, New Study Suggest (August 8, 2019)

Follow us

Facebook   Twitter   Pinterest   Tumblr   RSS   Newsletter via Email